Continuing its recent deal spree, Gilead Sciences has partnered with Nurix Therapeutics to discover, develop and commercialise a pipeline of targeted protein degradation drugs for the treatment of cancer and other challenging diseases. The multi-year deal, worth up to US$2.345 B, utilises Nurix’s technology platform to discover new drugs that will manipulate E3 ligases - the key enzymes that control protein levels in human cells.